Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliterator-activated receptor γ transcription

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 571-579

  Park, So Youn ^a   Shin, Hwa Kyoung ^b   Lee, Jeong Hyun ^a   Kim, Chi Dae ^a,b   Lee, Won Suk ^a   Yong Rhim, Byung ^a   Hong, Ki Whan ^a,b  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,3,9,10,11,12 HEXAHYDRO 10 HYDROXY 9 METHYL 1 OXO 9,12 EPOXY 1H DIINDOLO[1,2,3 FG:3',2',1' KL]PYRRO [3,4 I][1,6] BENZODIAZOCINE 10 CARBOXYLIC ACID HEXYL ESTER; ADIPONECTIN; CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FATTY ACID BINDING PROTEIN 4; FATTY ACID TRANSPORTER; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESISTIN; ROSIGLITAZONE; SUPEROXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; GLUCOSE TRANSPORTER 4; LEPTIN RECEPTOR; PHOSPHODIESTERASE INHIBITOR; SLC2A4 PROTEIN, MOUSE; TETRAZOLE DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; C57BL MOUSE; CAROTID ARTERY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; FIBROBLAST; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; BODY WEIGHT; CELL STRAIN 3T3; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; TRANSCRIPTION INITIATION;

3T3-L1 CELLS; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FIBROBLASTS; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 4; INSULIN; MALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; PPAR GAMMA; RECEPTORS, LEPTIN; TETRAZOLES; TRANSCRIPTIONAL ACTIVATION; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 65649096871     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.146456     Document Type: Article

References (37)

1. Arner P (2003) The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137-145.
2. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953.
3. Binnert C, Koistinen HA, Martin G, Andreelli F, Ebeling P, Koivisto VA, Laville M, Auwerx J, and Vidal H (2000) Fatty acid transport protein-1 mRNA expression in skeletal muscle and in adipose tissue in humans. Am J Physiol Endocrinol Metab 279:E1072-E1079.
4. Dawson DL, Cutler BS, Meissner MH, and Strandness DE Jr (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multi-center, randomized, prospective, double-blind trial. Circulation 98:678-686.
5. Fernández-Real JM and Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301.
6. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, and Dandona P (2006) Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91:3553-3558.
7. Goldstein BJ (2002) Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90:3G-10G.
8. Hotamisligil GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 24:S23-S27.
9. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, and Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663.
10. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, and Czerwiec F (2003) Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:2289-2302.
11. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y, and Nagai R (2006) C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis 185: 39-46.
12. Kim KY and Cheon HG (2006) Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor g-activated maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem 281:13503-13512.
13. Kim JA, Montagnani M, Koh KK, and Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113:1888-1904.
14. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A, Staels B, Fleck E, et al. (2002) PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91:e35-e44.
15. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, and Nakamura Y (2001) Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456.
16. Lazennec G, Canaple L, Saugy D, and Wahli W (2000) Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 14:1962-1975.
17. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, and Hong KW (2005) Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313:502-509.
18. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650.
19. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737.
20. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, and Olefsky JM (2005) JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280:35361-35371.
21. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476.
22. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, Kwak YG, Kim KY, and Hong KW (2006) Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317: 1238-1245.
23. Park SY, Lee JH, Kim KY, Kim EK, Yun SJ, Kim CD, Lee WS, and Hong KW (2008) Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription. Atherosclerosis 201:258-265.
24. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, and Hong KW (2005) Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattrac-tant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312:1241-1248.
25. Pasceri V, Willerson JT, and Yeh ET (2000) Direct proinflammatory effect of C-re-active protein on human endothelial cells. Circulation 102:2165-2168.
26. Prusty D, Park BH, Davis KE, and Farmer SR (2002) Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor γ (PPAR-γ) and C/EBPα gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem 277:46226- 46232.
27. Rangwala SM and Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-336.
28. Rea R and Donnelly R (2004) Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 6:163-170.
29. Rosen ED, Walkey CJ, Puigserver P, and Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14:1293-1307.
30. Sakaue H, Ogawa W, Matsumoto M, Kuroda S, Takata M, Sugimoto T, Spiegelman BM, and Kasuga M (1998) postranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase. J Biol Chem 273:28945-28952.
31. Shin HK, Kim YK, Kim KY, Lee JH, and Hong KW (2004) Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109:1022-1028.
32. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, and Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312.
33. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, and Mickle DA (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736-740.
34. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, and Flier JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422.
35. Watanabe M, Inukai K, Katagiri H, Awata T, Oka Y, and Katayama S (2003) Regulation of PPAR-γ transcriptional activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 300:429-436.
36. Werner AL and Travaglini MT (2001) A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21:1082-1099.
37. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295.